UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.

Petitioners,

V.

JAZZ PHARMACEUTICALS, INC., Patent Owner.

Case IPR2015-01903 Patent 8,731,963

PETITIONERS' MOTION TO WITHDRAW COUNSEL AND SUBSTITUTE NEW COUNSEL

Mail Stop "PATENT BOARD" Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450



I. RELIEF REQUESTED

Under 37 C.F.R. § 42.10(e), counsel for Petitioners Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc. request that the Board authorize withdrawal of counsel and substitution of new counsel. Patent Owner stated it does not oppose this motion.

II. STATEMENT OF FACTS SHOWING GOOD CAUSE FOR THE BOARD TO AUTHORIZE WITHDRAWAL OF COUNSEL

Petitioners Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc. wish to withdraw Aziz Burgy as Lead Counsel, substitute new Lead Counsel and add additional Backup Counsel in the above-captioned *inter partes* review proceeding. Specifically, Petitioners intend to appoint:

Lead Counsel	Backup Counsel
Janine A. Carlan (Reg. No. 42,387)	Richard J. Berman (Reg. No. 39,107)
Arent Fox LLP	Arent Fox LLP
1717 K Street NW	1717 K Street NW
Washington, DC 20006	Washington, DC 20006
(202) 857-6000	(202) 857-6000
janine.carlan@arentfox.com	richard.berman@arentfox.com
	Bradford C. Frese (Reg. No. 69,772)
	Arent Fox LLP
	1717 K Street NW
	Washington, DC 20006
	(202) 857-6000
	bradford.frese@arentfox.com

Petitioners' new Lead Counsel and Backup Counsel meet the requirements of 37 C.F.R. § 42.10(c) and are registered practitioners. In addition, Petitioners'



new counsel have read and intend to comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in Part 42 of the

C.F.R.

An executed Power of Attorney as authorized in the Notice of Filing Date

Accorded (Paper 5) is being filed concurrently.

A decision on whether to institute this *inter partes* review has already been

issued, and no extensions of time will be needed upon grant of this Motion.

Furthermore, it is believed that this Motion will not hinder the economy, the

integrity of the patent system, the efficiency of the Office, or the ability of the

Office to timely complete this proceeding. See 35 U.S.C. § 316(b).

Thus, Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc.

respectfully request that the Board grant this motion to withdraw counsel and

substitute new counsel. Updated Mandatory Notices Under 37 C.F.R. §42.8(b)(3)

and (b)(4) will be filed upon grant of the present motion.

Date: June 20, 2016 ARENT FOX LLP

1717 K Street, NW

Washington, DC 20006

202.857.6000

Respectfully Submitted,

Janine A. Carlan

Registration No. 42,387

Attorney for Petitioners

Par Pharmaceutical, Inc. and

Amneal Pharmaceuticals LLC



CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))

The undersigned hereby certifies that the above-captioned "Petitioners' Motion to Withdraw Counsel and Substitute New Counsel" was served in its entirety on June 20, 2016, upon the following parties via Electronic Mail:

F. Dominic Cerrito
QUINN EMANUEL URQUHART &
SULLIVAN LLP
51 Madison Avenue
22nd Floor
New York, NY 10010
NickCerrito@quinnemanuel.com

John V. Biernacki Jones Day North Point 901 Lakeside Avenue Cleveland, OH 44114 JVBiernacki@JonesDay.Com

Date: June 20, 2016 ARENT FOX LLP 1717 K Street, NW Washington, DC 20006 202.857.6000 Respectfully Submitted,

Bradford C. Frese Registration No. 69,772

Attorney for Petitioners

Par Pharmaceutical, Inc. and Amneal Pharmaceuticals LLC

